168 related articles for article (PubMed ID: 31619294)
1. The infectious thyroid nodule: a case report of mucormycosis associated with ibrutinib therapy.
Mascarella MA; Schweitzer L; Alreefi M; Silver J; Caglar D; Loo VG; Richardson K; Dufresne P; Lee TC; Sadeghi N
J Otolaryngol Head Neck Surg; 2019 Oct; 48(1):49. PubMed ID: 31619294
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib-associated T-cell pseudolymphoma.
Ho AKH; Koh XQ; Liau MMQ; Tan KB; Tan CL
Clin Exp Dermatol; 2019 Oct; 44(7):828-830. PubMed ID: 30623454
[No Abstract] [Full Text] [Related]
3. Probable Invasive Pulmonary Cryptococcosis and Possible Cryptococcal Empyema in CLL Treated With Frontline Ibrutinib.
Koehler AB; Vijayvargiya P; Ding W
Mayo Clin Proc; 2019 May; 94(5):915-917. PubMed ID: 31054610
[No Abstract] [Full Text] [Related]
4. Severe arthritic syndrome due to ibrutinib use for chronic lymphocytic leukemia.
Dasanu CA
J Oncol Pharm Pract; 2019 Jun; 25(4):1003-1005. PubMed ID: 29720040
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review.
Ghasoub R; Albattah A; Elazzazy S; Alokka R; Nemir A; Alhijji I; Taha R
J Oncol Pharm Pract; 2020 Mar; 26(2):487-491. PubMed ID: 31216242
[TBL] [Abstract][Full Text] [Related]
6. Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma.
Kreiniz N; Bejar J; Polliack A; Tadmor T
Hematol Oncol; 2018 Feb; 36(1):349-354. PubMed ID: 28156016
[TBL] [Abstract][Full Text] [Related]
7. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
[TBL] [Abstract][Full Text] [Related]
8. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.
Reda G; Fattizzo B; Cassin R; Mattiello V; Tonella T; Giannarelli D; Massari F; Cortelezzi A
J Hematol Oncol; 2018 Jun; 11(1):79. PubMed ID: 29891001
[TBL] [Abstract][Full Text] [Related]
9. New approved indication for ibrutinib.
Aschenbrenner DS
Am J Nurs; 2014 Jun; 114(6):21. PubMed ID: 24869579
[No Abstract] [Full Text] [Related]
10. Ibrutinib-induced polyneuropathy: A case report.
Cömert P; Albayrak M; Yıldız A; Şahin O; Öztürk HB; Reis Aras M
J Oncol Pharm Pract; 2020 Sep; 26(6):1501-1504. PubMed ID: 32028841
[TBL] [Abstract][Full Text] [Related]
11. Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer.
Varughese T; Taur Y; Cohen N; Palomba ML; Seo SK; Hohl TM; Redelman-Sidi G
Clin Infect Dis; 2018 Aug; 67(5):687-692. PubMed ID: 29509845
[TBL] [Abstract][Full Text] [Related]
12. Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia.
Lee A; Sandhu S; Imlay-Gillespie L; Mulligan S; Shumack S
Australas J Dermatol; 2017 Nov; 58(4):e240-e242. PubMed ID: 28295171
[TBL] [Abstract][Full Text] [Related]
13. Disseminated mucormycosis due to Lichtheimia corymbifera during ibrutinib treatment for relapsed chronic lymphocytic leukaemia: a case report.
Grossi O; Pineau S; Sadot-Lebouvier S; Hay B; Delaunay J; Miailhe AF; Bretonnière C; Jeddi F; Lavergne RA; Le Pape P
Clin Microbiol Infect; 2019 Feb; 25(2):261-263. PubMed ID: 30691617
[No Abstract] [Full Text] [Related]
14. Invasive aspergillosis with pulmonary and central nervous system involvement during ibrutinib therapy for relapsed chronic lymphocytic leukaemia: case report.
Peri AM; Bisi L; Cappelletti A; Colella E; Verga L; Borella C; Foresti S; Migliorino GM; Gori A; Bandera A
Clin Microbiol Infect; 2018 Jul; 24(7):785-786. PubMed ID: 29427802
[No Abstract] [Full Text] [Related]
15. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V
Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib for the treatment of chronic lymphocytic leukemia.
Deodato M; Frustaci AM; Zamprogna G; Cairoli R; Montillo M; Tedeschi A
Expert Rev Hematol; 2019 May; 12(5):273-284. PubMed ID: 30916599
[TBL] [Abstract][Full Text] [Related]
17. Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib.
Gülsaran SK; Baysal M; Demirci U; Baş V; Kirkizlar HO; Umit E; Demir AM
J Oncol Pharm Pract; 2020 Mar; 26(2):478-480. PubMed ID: 31142233
[TBL] [Abstract][Full Text] [Related]
18. Infection with ibrutinib in patients with chronic lymphocytic leukemia: How strong is the association?
Ball S; Vutthikraivit W; Maiti A; Short NJ
Eur J Haematol; 2018 Sep; 101(3):418-420. PubMed ID: 29791043
[No Abstract] [Full Text] [Related]
19. Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study.
Ruchlemer R; Ben-Ami R; Bar-Meir M; Brown JR; Malphettes M; Mous R; Tonino SH; Soussain C; Barzic N; Messina JA; Jain P; Cohen R; Hill B; Mulligan SP; Nijland M; Herishanu Y; Benjamini O; Tadmor T; Okamoto K; Arthurs B; Gottesman B; Kater AP; Talha M; Eichhorst B; Korem M; Bogot N; De Boer F; Rowe JM; Lachish T
Mycoses; 2019 Dec; 62(12):1140-1147. PubMed ID: 31520441
[TBL] [Abstract][Full Text] [Related]
20. Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia.
Chan TS; Au-Yeung R; Chim CS; Wong SC; Kwong YL
Ann Hematol; 2017 May; 96(5):871-872. PubMed ID: 28184982
[No Abstract] [Full Text] [Related]
[Next] [New Search]